The role of hepatitis B vaccine challenge dose in patients with underlying health conditions.
HBV
Italy
health care workers
immunocompromised
vaccination
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
3
7
2020
medline:
23
6
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
We have evaluated the immunological response to Hepatitis B virus (HBV) booster vaccine dose in 129 adults with underlying diseases in comparison with 694 subjects at occupational risk of infection, who have previously completed the primary series and resulted with anti-HBs <10 mIU/mL. After booster dose, 60.5% of the patients with underlying diseases and 14.8% of the subjects at occupational risk resulted seronegative. By comparing two groups, rate of subjects with anamnestic response was higher in at occupational risk group respect to that at risk for medical conditions (OR: 5.99 [95%IC, 3.81-9.41],
Identifiants
pubmed: 32614653
doi: 10.1080/21645515.2020.1777058
pmc: PMC7899643
doi:
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Surface Antigens
0
Hepatitis B Vaccines
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-579Références
AIDS. 2005 Mar 24;19(6):593-601
pubmed: 15802978
J Hepatol. 2006;44(1 Suppl):S6-9
pubmed: 16352363
MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33; quiz CE1-4
pubmed: 17159833
AIDS Patient Care STDS. 2010 Jul;24(7):403-7
pubmed: 20586648
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):363-7
pubmed: 11338063
Transplant Proc. 1998 May;30(3):797-9
pubmed: 9595103
Adv Virol. 2013;2013:196704
pubmed: 23840211
Am J Transplant. 2015 May;15(5):1162-72
pubmed: 25707744
Rev Med Virol. 2017 Nov;27(6):
pubmed: 28905444
J Infect Dis. 2009 Nov 1;200(9):1390-6
pubmed: 19785526
J Infect Dis. 2009 Sep 15;200(6):935-46
pubmed: 19663708
Ann Intern Med. 1988 Jul 15;109(2):101-5
pubmed: 2968064
Braz J Infect Dis. 2008 Aug;12(4):306-9
pubmed: 19030730
J Infect Dis. 2013 Feb 1;207(3):402-10
pubmed: 23175769
Am J Med Sci. 1999 Nov;318(5):304-7
pubmed: 10555092
Vaccine. 2009 Jan 1;27(1):17-22
pubmed: 18984022
Vaccine. 2000 Jan 18;18(13):1161-5
pubmed: 10649616
Hum Vaccin Immunother. 2017 Feb;13(2):440-444
pubmed: 27925503
Lancet. 2002 Dec 14;360(9349):1921-6
pubmed: 12493258
Lancet Infect Dis. 2012 Dec;12(12):966-76
pubmed: 23174382
AIDS. 1992 May;6(5):509-10
pubmed: 1535502
Digestion. 2020;101 Suppl 1:58-68
pubmed: 31968344
Vaccine. 2013 Feb 4;31(7):1040-4
pubmed: 23273969
Clin Microbiol Infect. 2012 Oct;18 Suppl 5:93-9
pubmed: 23051059
Vaccine. 2009 Jul 23;27(34):4731-8
pubmed: 19540026
Infect Dis Ther. 2017 Sep;6(3):303-331
pubmed: 28779442
AIDS Rev. 2009 Jul-Sep;11(3):157-64
pubmed: 19654857
Liver Transpl. 2001 Apr;7(4):314-20
pubmed: 11303291
J Infect Dis. 2008 Jan 15;197(2):292-4
pubmed: 18177248
Scand J Infect Dis. 2008;40(1):54-8
pubmed: 17852939
Lancet Infect Dis. 2015 Nov;15(11):1283-91
pubmed: 26257021
Hum Vaccin Immunother. 2020 Apr 2;16(4):949-954
pubmed: 31634048
Can J Gastroenterol. 2000 Jul-Aug;14 Suppl B:59B-62B
pubmed: 10938507
AIDS Res Hum Retroviruses. 2018 Nov;34(11):922-928
pubmed: 29926738
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
PLoS One. 2014 Aug 21;9(8):e105591
pubmed: 25144773
Int J STD AIDS. 2009 Sep;20(9):595-600
pubmed: 19710329
BMC Infect Dis. 2006 Mar 30;6:65
pubmed: 16571140
J Prev Med Hyg. 2019 Sep 30;60(3):E184-E190
pubmed: 31650052